Literature DB >> 19557465

[Urine-based markers of angiogenesis in bladder cancer].

M Becker1, D Tilki, T Szarvas, H Rübben, S Ergün.   

Abstract

Angiogenesis is a prerequisite for tumour growth and metastasis. Therefore, angiogenesis factors in bladder cancer, a common disease of the genitourinary tract, could serve as diagnostic tools, predictors of prognosis, and targets for therapy. Development of less invasive or noninvasive detection techniques, reliable prognostic markers, and individualized targeted therapy would have a significant impact on disease management. For this investigative goal, the utility of urine and blood is beneficial. Research in the field of angiogenesis and promising markers is currently evolving. In spite of the recent success of antiangiogenic agents in the oncological clinic, an optimal marker that will warrant substitution of the cystoscopic follow-up protocol in patients with urothelial neoplasms has not been identified yet. Despite this challenge, allocating more resources and attention to identifying such urine markers is justified to optimize the diagnostics and follow-up of urinary bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19557465     DOI: 10.1007/s00120-009-1989-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  47 in total

1.  A review of Judah Folkman's remarkable achievements in biomedicine.

Authors:  Yihai Cao; Robert Langer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-04       Impact factor: 11.205

Review 2.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

3.  Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.

Authors:  Vasilios E Theodoropoulos; Andreas C Lazaris; Ioannis Kastriotis; Chariclia Spiliadi; George E Theodoropoulos; Vasiliki Tsoukala; Efstratios Patsouris; Frank Sofras
Journal:  BJU Int       Date:  2005-02       Impact factor: 5.588

4.  Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer.

Authors:  Natsuo Oka; Yasuyo Yamamoto; Masayuki Takahashi; Masaaki Nishitani; Hiro-Omi Kanayama; Susumu Kagawa
Journal:  BJU Int       Date:  2005-03       Impact factor: 5.588

5.  Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential.

Authors:  S Gravas; I Bosinakou; P Kehayas; A Giannopoulos
Journal:  Urol Int       Date:  2004       Impact factor: 2.089

6.  Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers.

Authors:  M Nguyen; H Watanabe; A E Budson; J P Richie; D F Hayes; J Folkman
Journal:  J Natl Cancer Inst       Date:  1994-03-02       Impact factor: 13.506

Review 7.  Angiopoietins in tumours: the angiogenic switch.

Authors:  Catherine R Tait; Pamela F Jones
Journal:  J Pathol       Date:  2004-09       Impact factor: 7.996

8.  Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.

Authors:  A Takahashi; H Sasaki; S J Kim; K Tobisu; T Kakizoe; T Tsukamoto; Y Kumamoto; T Sugimura; M Terada
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

9.  Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells.

Authors:  S J Mandriota; G Seghezzi; J D Vassalli; N Ferrara; S Wasi; R Mazzieri; P Mignatti; M S Pepper
Journal:  J Biol Chem       Date:  1995-04-28       Impact factor: 5.157

Review 10.  Recent developments in the cell biology of basic fibroblast growth factor.

Authors:  D B Rifkin; D Moscatelli
Journal:  J Cell Biol       Date:  1989-07       Impact factor: 10.539

View more
  1 in total

1.  [Plasma E-cadherin levels in urinary bladder cancer: does it improve risk stratification?].

Authors:  T Szarvas; F Hoffmann; M Becker; M Schenck; F Vom Dorp; H Rübben; T Jäger
Journal:  Urologe A       Date:  2011-01       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.